^
BRAF V600E
Ganglioglioma
trametinib + dabrafenib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
vemurafenib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
trametinib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
dabrafenib
Sensitive: A2 - Guideline
BRAF V600
Ganglioglioma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
Ganglioglioma
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600
Ganglioglioma
vemurafenib + cobimetinib
Sensitive: C1 - Off-label
BRAF V600
Ganglioglioma
BRAF inhibitor + MEK inhibitor
Sensitive: C3 – Early Trials
BRAF T599
Ganglioglioma
trametinib + dabrafenib
Sensitive: C4 – Case Studies